Table 1.
Demographic and hematopoietic stem cell transplant variables and their association with survival.
| All patients (n = 473) |
Survivors (n = 438) |
Deaths (n = 35) |
p (1) | OR of Survival [95% CI] |
|
|---|---|---|---|---|---|
| Demographic | |||||
| Age, median [25%ile–75%ile], years | 8 [3–15] | 8 [3–15] | 6 [1–15] | 0.41 (2) | |
| Male, n (%) | 284 (60) | 265 (93) | 19 (7) | 0.47 (3) | 1.29 [0.65–2.58] |
| Female, n (%) | 189 (40) | 173 (92) | 16 (8) | ||
| Race and ethnicity, n (%) | |||||
| Caucasian | 322 (68) | 299 (93) | 23 (7) | 0.96 (4) | |
| African American | 69 (15) | 63 (91) | 6 (9) | ||
| Asian/Pacific Islander | 21 (4) | 20 (95) | 1 (5) | ||
| Hispanic | 26 (6) | 24 (92) | 2 (8) | ||
| Other/Unknown | 35 (7) | 32 (91) | 3 (9) | ||
| Hospital LOS, median [25%ile–75%ile], days | 32 [23–47] | 31 [23–43] | 85 [63–116] | <0.01 (5) | |
| Transplant Type | |||||
| Allogeneic, n (%) | 293 (62) | 262 (89) | 31 (11) | <0.01 (6) | 0.19 [0.07–0.55] |
| Autologous, n (%) | 180 (38) | 176 (98) | 4 (2) | ||
| Transplant Indication | 0.02 (7) | ||||
| Malignant Hematologic, n (%) | 221 (47) | 199 (90) | 22 (10) | REF (7) | |
| Solid tumor, n (%) | 157 (33) | 153 (97) | 4 (3) | <0.01 (7) | 4.23 [1.43–12.53] |
| Non-malignant Hematologic, n (%) | 64 (14) | 59 (92) | 5 (8) | 0.81 (7) | 1.30 [0.47–3.59] |
| Immunodeficiency, n (%) | 21 (4) | 18 (86) | 3 (14) | 0.46 (7) | 0.66 [0.18–2.43] |
| Non-malignant other, n (%) | 10 (2) | 9 (90) | 1 (10) | 1.00 (7) | 0.99 [0.12–8.23] |
OR, odds ratio; CI, confidence interval; NS, not significant, LOS, length of stay; REF, reference group.
(1) Continuous variables compared with Wilcoxon rank sums tests. Categorical variables were compared with Pearson's χ2 or Fisher's Exact, and post hoc multiple comparisons were performed when the primary comparison was significant (see Methods).
(2) Comparison of age medians, survivors vs. deaths.
(3) Comparison of sex distributions, survivors vs. deaths.
(4) Comparison of race and ethnicity distributions, survivors vs. deaths.
(5) Comparison of hospital LOS medians, survivors vs. deaths.
(6) Comparison of transplant type distributions, survivors vs. deaths.
(7) Comparison of transplant indication distributions, survivors vs. deaths. Malignant hematologic subgroup served as reference group for post hoc multiple comparisons. See Supplementary Appendix for individual diagnoses included in each transplant indication subgroup.